Proactiveinvestor8 Jul 2011 09:29
Biotech testing services firm Cyprotex (LON:CRX) has made a deal with Hungary’s Solvo Biotechnology that will help its pharmaceutical customers further de-risk drug candidates before they are used in human trials.
Cyprotex is the world’s largest contract research body that specialises in ADME Tox – the analysis of the absorption, distribution, metabolism, excretion and toxicity properties of potential drugs, cosmetics and agrochemicals. This is a key process in checking the beneficial and adverse effects of a drug on living matter.
Solvo Biotechnology is a specialist in ‘drug transporters’ – a family of proteins that actively move substances across cellular membranes, both into and out of cells. In recent years, drug transporters have been recognised as playing an important role in pharmacokinetics – the process by which a drug is absorbed, distributed, metabolised and eliminated by the body – and they have been identified as responsible for toxicities and drug-drug interactions that were not previously understood.
Under the agreement announced today, Cyprotex will offer Solvo Biotechnology’s drug-transporter services to its customers.
“The role of drug transporters in causing toxicities and drug-drug interactions has only recently become understood,” said Dr Katya Tsaioun, Cyprotex’s chief scientific officer. “The US [Food and Drug Administration] has moved quickly in recommending in vitro testing for drug-transporter activity at the preclinical stage. As Cyprotex is committed to serving all of our clients' preclinical ADME-Tox needs, and as Solvo Biotechnology has over a decade of focus on transporters and deep expertise in this field, Cyprotex is delighted to partner with Solvo Biotechnology for providing these services which pharmaceutical companies need for de-risking their drug candidates before human clinical trials.”
Sign In
Follow the stocks
